KUALA LUMPUR: Pharmaniaga Bhd's net profit decreased 7.03 per cent to RM17.59 million for the first-quarter (Q1) ended March 31, 2018 as compared to RM18.92 million in the same period a year ago.
In an exchange filing today, Pharmaniaga’s Q1 revenue dipped 0.06 per cent to RM617.92 million from RM618.29 million.
The group has also declared a first interim dividend of five sen per share, payable on June 20, 2018.
Chairman Tan Sri Lodin Wok Kamaruddin said the company’s Q1 results showed the consistent value delivered to shareholders amid tough market conditions.
He noted the performance of the company was achieved by solid contributions from it’s business segments, particularly the private sector business in tandem with its continuous efforts towards operational excellence and cost efficiency.
“Looking ahead, the group is on track to deliver its business strategy of market driven-growth and continuous operational improvements.
“We will continue to focus on tapping opportunities in domestic and international markets, with new product offerings driven by research and development; while at the same time continuing to implement initiatives that will move the needle across our operational value chain, to positively impact our cost efficiency and productivity.
Lodin has raised his confidence that the company’s two-pronged strategy will enable to effectively leverage on the bright prospects in the global healthcare sector, and thereafter maintain its momentum.